REGENXBIO Inc. (NASDAQ:RGNX) shares, rose in value on Friday, 05/13/22, with the stock price up by 5.31% to the previous day’s close as strong demand from buyers drove the stock to $20.84.
Actively observing the price movement in the last trading, the stock closed the session at $19.79, falling within a range of $20.26 and $21.412. The value of beta (5-year monthly) was 1.01 whereas the PE ratio was 9.85 over 12-month period. Referring to stock’s 52-week performance, its high was $46.46, and the low was $19.07. On the whole, RGNX has fluctuated by -33.01% over the past month.
With the market capitalization of REGENXBIO Inc. currently standing at about $978.44 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 28, 2022 – Mar 04, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $4.71, which is expected to increase to -$1.23 for fiscal year $1.31 and then to about -$4.05 by fiscal year 2022. Data indicates that the EPS growth is expected to be 144.00% in 2022, while the next year’s EPS growth is forecast to be -409.20%.
Analysts have estimated the company’s revenue for the quarter at $271.74 million, with a low estimate of $30 million and a high estimate of $495.6 million. According to the average forecast, sales growth in current quarter could jump up 1,167.10%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $329.36 million, representing an increase of 113.10% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RGNX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 4.93, with the price of RGNX currently trading nearly -21.97% and -28.25% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.70, while the 7-day volatility ratio is showing 9.19% which for the 30-day chart, stands at 7.04%. Furthermore, REGENXBIO Inc. (RGNX)’s beta value is 1.08, and its average true range (ATR) is 1.80.
Data on historical trading for REGENXBIO Inc. (NASDAQ:RGNX) indicates that the trading volumes over the past 10 days have averaged 0.5 million and over the past 3 months, they’ve averaged 402.11K. According to company’s latest data on outstanding shares, there are 42.94 million shares outstanding.
Nearly 1.30% of REGENXBIO Inc.’s shares belong to company insiders and institutional investors own 90.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.51 million shares as on Feb 14, 2022, resulting in a short ratio of 5.43. According to the data, the short interest in REGENXBIO Inc. (RGNX) stood at 5.87% of shares outstanding as of Feb 14, 2022; the number of short shares registered in Jan 13, 2022 reached 3.09 million. The stock has fallen by -36.27% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RGNX stock heading into the next quarter.